Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development

VANCOUVER, BC / ACCESS Newswire / April 17, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointments of Dr. Islam Mohamed as Chief Medical Officer (CMO) and Stephen M. Novak as Chief of Research and Development (R&D). These strategic leadership additions are intended to strengthen the Company's clinical and development capabilities as it advances its lead product candidate, ONC010, also known as its PNKP Inhibitor Technology, toward first-in-human studies.

The appointments come at a critical inflection point for Onco-Innovations as the Company transitions from advanced preclinical development into clinical-stage execution. Together, Dr. Mohamed and Mr. Novak will lead an integrated clinical and development strategy designed to accelerate regulatory readiness, optimize program execution, and support long-term value creation.

Dr. Islam Mohamed joins Onco-Innovations as Chief Medical Officer with extensive experience in clinical medicine, translational research, and global drug development. In this role, Dr. Mohamed will oversee the Company's clinical strategy, including protocol design, medical oversight, and regulatory engagement, ensuring that all clinical programs are aligned with the highest standards of scientific rigour and patient safety. He will play a central role in advancing Onco's PNKP Inhibitor Technology Program through Investigational New Drug (IND)-enabling activities and into early-stage clinical trials, while fostering relationships with investigators, regulatory agencies, and key opinion leaders.

Stephen M. Novak assumes the role of Chief of Research and Development, bringing over 25 years of executive leadership experience across biotechnology, clinical development, regulatory strategy, and large-scale operational environments. Mr. Novak will lead the Company's end-to-end development operations, including Chemistry, Manufacturing, and Controls (CMC), preclinical development, manufacturing scale-up, and global program execution. He has a demonstrated track record of advancing complex therapeutic programs from preclinical through Phase I-III development, with deep expertise in Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) oversight, regulatory readiness, and global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) partnerships.